Engineered lysin-human defensin protein
AssigneeUniversity of South Florida
InventorXingmin Sun
Life of this patent
Estimating the term…
Abstract
Clostridium difficile, reclassified as Clostridioides difficile, is a Gram-positive, spore-forming, anaerobic, and toxin-producing nosocomial pathogen. Since the first description of a C. difficile-associated disease (CDAD)-like case in 1892, C. difficile infection (CDI) has become a high-impact health care-associated infection throughout the world, especially in the developed countries. Described herein are methods of treating Clostridium difficile infection in a subject in need thereof by administering an amount of the engineered lysin-human defensin (LHD) protein(s) described herein.
Claims13
A recombinant lysin-human defensin (LHD) protein comprising a catalytic domain of a lysin protein of C. difficile phage phiC2 comprising the amino acid sequence of SEQ ID NO:2, wherein the lysin protein is operatively coupled via a linker comprising the amino acid sequence of SEQ ID NO:4 (GGGGS)3 to a human alpha-defensin 5 polypeptide comprising the amino acid sequence of SEQ ID NO:
- 3, wherein the recombinant lysin-human defensin protein is capable of specifically lysing Clostridium difficile.
Dependencies are inferred from the claim text.